<DOC>
	<DOCNO>NCT02663076</DOCNO>
	<brief_summary>The multicenter registry collect clinical data 2500 patient non valvular atrial fibrillation ( NVAF ) chronic kidney disease ( eGFR 15-49 mL/min per 1.73 m2 ) . The overall objective registry ass chronic kidney disease ( CKD ) progression clinical outcome regard anticoagulation strategy NVAF patient eGFR 15-49 mL/min per 1.73 m2 routine clinical practice .</brief_summary>
	<brief_title>Factor XA - Inhibition RENal Patients With Non-valvular Atrial Fibrillation - Observational Registry</brief_title>
	<detailed_description>This prospective registry allow structure , non-interventional collection data . Participating physician subject instruction regard diagnosis therapy patient . All patient treatment carry within clinical routine , discretion physician accord exist treatment guideline . This registry carry investigator-initiated , multicentre , prospective , non-interventional observational registry approximately 100 site Germany , Austria Switzerland . The registry collect clinical data approximately 2500 patient CKD ( eGFR 15-49 mL/min per 1.73 m2 ) NVAF receive rivaroxaban , OAC VKA , AC therapy , prospectively follow flexible duration least 12 month ( last enrolled patient ) estimate mean 18 month whole study cohort . It plan include 1000 patient rivaroxaban therapy VKA therapy , respectively . Enrolment prolong beyond 2500 patient 1000 rivaroxaban patient enrol .</detailed_description>
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Rivaroxaban</mesh_term>
	<criteria>male female patient , age ≥ 18 year CKD eGFR 15 49 mL/min per 1.73 m2 nonvalvular atrial fibrillation ( NVAF ) indication anticoagulation therapy treatment strategy ≥ 3 previous month enrolment either : rivaroxaban VKA ( OAC cohort ) anticoagulation ( AC cohort ) inform consent availability follow life expectancy ≥6 month exclusion criterion accord local product information respective anticoagulation treatment plan treatment anticoagulant expect renalreplacement therapy within next 3 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>